Item 1.01 Entry into a Material Definitive Agreement.
On
The Company is not obligated to make any sales of Common Stock under the 2021 Sales Agreement. The offering of Placement Shares pursuant to the 2021 Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the 2021 Sales Agreement or (ii) termination of the 2021 Sales Agreement in accordance with its terms.
Upon delivery of a placement notice and subject to the terms and conditions of the 2021 Sales Agreement, Cowen may sell the Placement Shares by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Global Select Market or on any other existing trading market for the Common Stock. Cowen will use commercially reasonable efforts to sell the Placement Shares from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay Cowen a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through Cowen under the 2021 Sales Agreement, and also has provided Cowen with customary indemnification and contribution rights.
The foregoing description of the 2021 Sales Agreement is qualified in its
entirety by reference to the full text of the 2021 Sales Agreement, which is
attached as Exhibit 1.2 to the Company's Form S-3 filed
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any shares under the 2021 Sales Agreement, nor shall there be any offer, solicitation, or sale of such shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Item 5.03 Amendments to Articles of Incorporation or Bylaws.
On
--------------------------------------------------------------------------------
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description 3.1* Certificate of Correction toG1 Therapeutics, Inc.'s Amended and Restated Certificate of Incorporation filed onMay 22, 2017 , datedJune 30, 2021 . 5.1 Opinion ofMintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C ., datedJuly 2, 2021 (incorporated by reference as Exhibit 5.1 to the Company's Registration Statement on Form S-3ASR filed with theSEC onJuly 2, 2021 ). 10.1 Sales Agreement, dated as ofJuly 2, 2021 , by and betweenG1 Therapeutics, Inc. andCowen and Company, LLC (incorporated by reference as Exhibit 1.2 to the Company's Registration Statement on Form S-3ASR filed with theSEC onJuly 2, 2021 ). 23.1 Consent ofMintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C . (contained in Exhibit 5.1 above). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith.
--------------------------------------------------------------------------------
© Edgar Online, source